Squamous cell carcinoma case shows 8-week genetic testing delay from local referral chain

The patient documented repeated scheduling friction at a community ENT practice, securing an earlier slot only through repeated callback persistence after an initial 4-week wait. Subsequent genetic panel orders stalled when the surgeon deferred to an external oncologist, shifting sample source from biopsy to post-surgical tumor and extending turnaround by multiple months. NCCN guidelines explicitly list upfront comprehensive profiling for head and neck squamous cell carcinoma yet contain no enforcement mechanism for ordering speed.

US News 2024-2025 cancer hospital rankings place MD Anderson at rank 1 for speed of multidisciplinary coordination; the same case at that center yielded a pathologist consult within 20 minutes versus an unanswered query at the local site. Sijbrandij Foundation materials emphasize patient-initiated second reads and volume queries, steps the author later identified as omitted. No published benchmark quantifies how often community practices meet NCCN timing targets for biomarker results.

Operationally, the record indicates that distance to an NCI-designated center under 3 hours correlates with faster iteration on staging and treatment sequencing. Patients within that radius should route initial consults there rather than default to local hospitals even when insurance networks include both. Follow-up data collection on testing intervals at ranked versus unranked facilities remains absent from current registries.

Next measurable threshold is whether 2025 NCCN updates add explicit 14-day genetic turnaround metrics with audit requirements for participating centers.